logo-loader
HealthPharma & Biotech
viewTissue Regenix Group PLC

Tissue Regenix Group PLC making progress on all fronts – Jefferies

Regenerative medtech Tissue Regenix Group PLC is making clear progress on all fronts, said heavyweight US broker Jefferies today, which rates the shares a 'buy'.

knee.jpg
But Jefferies reckons the group's orthopedic products - OrthoPure - will provide the next leg of growth....

Regenerative medtech Tissue Regenix Group PLC (LON:TRX) is making clear progress on all fronts, said heavyweight US broker Jefferies today, which rates the shares a 'buy'.

The group is a wound care expert, with its Dermapure product being used to rebuild cells in the most difficult of wounds.

The broker noted that product (Dermapure ) has now surpassed the $1mln revenue mark and with nine of 11 medicare administrators secured (and promising private payor progress) analyst Chris Cooper expect further acceleration through full year 16/17, particularly now the "hybrid sales model is well established and senior sales directors are in place".

But Jefferies reckons the group's orthopedic products - OrthoPure -  will  provide the next leg of growth and will provide meaningful revenues from the first half of the 2017/18 year.

More than 1.5mln people suffer meniscal injuries in the US and EU alone, of which OrthoPure XM would likely target 300,000, it notes.

"The other key franchise in the orthopedics portfolio is OrthoPure XT (ACL repair), for which the trial commenced in Dec-15 with first results likely in 1H16/17. The company is on target to launch the human tissue orthopedic products in the US by end-FY16/17," added Cooper.

Also significant, the firm was granted last week US regulatory clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue, signalling a commercial launch in the US later this year.

"We estimate FY17 Dermapure/ Surgipure sales of $9m/$0.6m, with $2.9m from Orthopure by FY18. We continue to view orthopedics as the greater LT value driver and are encouraged by progress to date," concluded the analyst.

Jefferies raises the price target to 37p from 36p  - which is more than double the  current share price of 17.5p.

Quick facts: Tissue Regenix Group PLC

Price: 3.2 GBX

AIM:TRX
Market: AIM
Market Cap: £37.5 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016

2 min read